Relationships between several markers of extracellular matrix turn-over and ultrasonography in human schistosomiasis mansoni

American Journal of Tropical Medicine and Hygiene

Volumn 60, Issue 4, 1999, Pages 658-663

  Ricard Blum, S ^a   Hartmann, D J ^b   Grenard, P ^c   Ravaoalimalala, V E ^d   Boisier, P ^d   Esterre, P ^e,f  

^a INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^b Inst Sci Pharmaceutiques B   (France)

^c INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^d INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

^e Inst Terr Rech Medicales Louis M   (French Polynesia)

^f Inst Rech Medicales Louis Malarde   (French Polynesia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; HYALURONIC ACID; PRAZIQUANTEL; PYRIDINOLINE; SCLEROPROTEIN;

ARTICLE; DISEASE MARKER; DISEASE SEVERITY; ECHOGRAPHY; EXTRACELLULAR MATRIX; HOST PARASITE INTERACTION; HUMAN; PROTEIN DEGRADATION; SCHISTOSOMIASIS;

EID: 0032959257     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.60.658     Document Type: Article

References (38)

1. Boros DL, 1989. Immunopathology of Schistosoma mansoni infection. Clin Microbiol Rev 2: 250-269.
2. James S, Colley D, 1995. Schistosomiasis. Current Opin Infect Dis 8: 351-355.
3. World Health Organization, 1985. The control of schistosomiasis. Report of a WHO Expert Committee Technical Report. World Health Organ Tech Rep Ser 728.
4. Capron A, Dessaint JP, Capron M, Ouma JH, Butterworth AE, 1987. Immunity to schistosomes: progress toward vaccines. Science 238: 1065-1072.
5. Capron A, Dessaint JP, Capron M, Pierce RJ, 1992. Vaccine strategies against schistosomiasis. Immunobiology 184: 282-294.
6. Dunne DW, Hagan P, Abath FGC, 1995. Prospects for immunological control of schistosomiasis. Lancet 345: 1488-1492.
7. Wiest PM, 1996. The epidemiology of morbidity of schistosomiasis. Parasitol Today 12: 215-220.
8. Boisier P, Serieye J, Ravaoalimalala VE, Roux J, Esterre P, 1995.Ultrasonographical assessment of morbidity in schistosomiasis mansoni in Madagascar: a community-based study in rural population. Trans R Soc Trop Med Hyg 89: 208-212.
9. Homeida M, Abdel-Gadir AF, Cheever AW, Bennet JL, Arbab BMO, Ibrahium SZ, Abdel-Salam IM, Dafalla AA, Nash TE, 1988. Diagnosis of pathologically confirmed Symmer's periportal fibrosis by ultrasonography: a prospective blinded study. Am J Trop Med Hyg 38: 86-91.
10. Hatz C, Savioli L, Mayombana C, Dhunputh J, Kisumku UM, Tanner M, 1990. Measurement of schistosomiasis-related morbidity at community levels in areas of different endemicity. Bull World Health Organ 68: 777-787.
11. Risteli J, Risteli L, 1995. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 22 (suppl 2): 77-81.
12. Schuppan D, Stölzel U, Oesterling C, Somasundaram R, 1995. Serum assays for liver fibrosis. J Hepatol 22 (suppl 2): 82-88.
13. Zwingenberger K, Harma G, Feldmeier H, Muller O, Steiner A, Bienzle U, 1988. Liver involvement in human schistosomiasis mansoni. Regression of immunological and biochemical disease markers after specific treatment. Acta Trop 45: 263-275.
14. Hassanein HI, Zoheiry MMK, Voss B, El Attar GM, Hassan SI, Demerdash ZA, El Baz HMG, Yousif OA, 1997. Effect of early treatment with praziquantel on serum connective tissue metabolite markers in children and adolescents with intestinal schistosomiasis mansoni. Arzneim Forsch/Drug Res 47: 84-88.
15. Hartmann DJ, Trinchet JC, Ricard-Blum S, Beaugrand M, Callard P, Ville G, 1990. Radioimmunoassay of type I collagen that mainly detects degradation products in serum. Application to patients with liver diseases. Clin Chem 36: 421-426.
16. Hartmann D, 1995. Serum determination of type I and type III collagens by radioimmunoassay. Application for liver diseases. J Hepatol 22 (suppl 2): 100-102.
17. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L, 1993. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 636-640.
18. Ricard-Blum S, Bresson-Hadni S, Vuitton DA, Ville G, Grimaud JA, 1992. Hydroxypyridinium collagen cross-links in human liver fibrosis: study of alveolar echinococcosis. Hepatology 15: 599-602.
19. Ricard-Blum S, Ville G, Grimaud JA, 1992. Pyridinoline, a mature collagen cross-link, in fibrotic livers from Schistosoma mansoni-iniected mice. Am J Trop Med Hyg 47: 816-820.
20. Ricard-Blum S, Liance M, Houin R, Grimaud JA, Vuitton DA, 1995. Covalent cross-linking of liver collagen by pyridinoline increases in the course of experimental alveolar echinococcosis. Parasite 2: 113-118.
21. Ricard-Blum S, Bresson-Hadni S, Guerret S, Grenard P, Volle JP, Risteli L, Grimaud J., Vuitton DA, 1996, Mechanism of collagen network stabilization in human irreversible granulomatous liver fibrosis. Gastroenterology 111: 172-182.
22. Grenard P, Blanquier B, Ricard-Blum S, 1997. The urinary excretion of the collagen cross-link pyridinoline increases during liver fibrogenesis. J Hepatol 26: 1356-1362.
23. Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J. Poupon R, 1994. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 20: 388-393.
24. Remmel T, Remmel H, Salupere V, 1996. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis. J Gastroenterol Hepatol 11: 1016-1020.
25. Takamatsu S, Nakabayashi H, Okamoto Y, Nakano H, 1997. Noninvasive determination of liver collagen content in chronic hepatitis. Multivariate regression modeling with blood chemical parameters as variables. J Gastroenterol 32: 355-360.
26. Esterre P, Raobelison A, Ramarokoto CE, Ravaoalimalala VE, Boisier P, Roux J, 1998. Serum concentrations of s-ICAM-1, sE-, sL- and sP-selectins in patients with Schistosoma mansoni infection and association with disease severity. Parasite Immunol 20: 369-376.
27. Morvan JM, Boisier P, Roux JF, 1994. Anti-HCV antibody prevalence among an asymptomatic population living in two villages in Madagascar. Trans R Soc Trop Med Hyg 88: 657.
28. Ricard-Blum S, Chossegros P, Guerret S, Trepo C, Grimaud JA, Chevallier M, 1996. The carboxy-terminal crosslinked telopeptide of type I collagen (ICTP) is a potential marker of ongoing liver fibrosis. Clin Chim Acta 248: 187-195.
29. Slot C, 1965. Plasma creatinine determination: a new and specific Jaffe reaction method. J Clin Lab Invest 17: 381-387.
30. Ricard-Blum S, Grenard P, Bresson-Hadni S, Guerret S, Chossegros P, Chevallier M, Risteli L, Vuitton DA, 1997. Investigation of collagen cross-linking at the urinary and tissue levels in human liver fibrosis. Wisse E, Knook DL, Balabaud C, eds. Cells of the Hepatic Sinusoid. Volume 6. Leiden, The Netherlands: The Kupffer Cell Foundation, 62-63.
31. Fayol V, Hassanein HI, El-Badrawy N, Ville G, Hartmann DJ, 1991. Aminoterminal propeptide of type III collagen: a marker of disease activity in schistosomal patients. Eur J Clin Chem Clin Biochem 29: 737-741.
32. Shahin M, Schuppan D, Waldherr R, Risteli J, Risteli L, Savolainen E-R, Oesterling C. Abdel Rahman HM, El Sahly AM, Abdel Razek SM, El Ruby O, Koch A, Seitz HK, 1992. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schis-tosomiasis and alcoholic liver disease. Hepatology 35: 637-644.
33. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R, 1995. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 22: 22-26.
34. Yamada M, Fukuda Y, Koyama Y, Nakano I, Urano F, Katano Y, Hayakawa T, 1996. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 11: 646-651.
35. Trottein F, Nutten S, Papin JP, Leportier C, Poulain-Godefroy O, Capron A, Capron M, 1997. Role of adhesion molecules of the selectin-carbohydrate families in antibody-dependent cell-mediated cytotoxicity to schistosome targets. J Immunol 159: 804-811.
36. Jacobs W, Bogers J, Deelder A, van Marck E, 1997. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in experimental Schistosoma mansoni infection and in synchronous periparticular hepatic granulomas in mice. Parasitol Res 83: 405-412.
37. Lejoly-Boisseau H, Blann AD, Seigneur M, Tribouley-Duret J, Tribouley J, Boisseau MR, 1996. Endothelium activation released increase of soluble intercellular adhesion molecule-1 in human schistosomiasis. Eur J Clin Invest 26: 522-523.
38. Secor WE, Dos Reis MG, Ramos EA, Matos EP, Reis EA, Do Carmo TM, Harn DA, 1994. Soluble intercellular adhesion molecules in human schistosomiasis: correlations with disease severity and decreased responsiveness to egg antigens. Infect Immun 62: 2695-2701.